Overview

Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

This is an international, randomized, open-label, controlled, multicenter phase II clinical trial to investigate and compare the safety and efficacy of palbociclib combined with fulvestrant or letrozole in women with ER+, HER2- locally advanced or metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

MedSIR

Treatments:

Estradiol
Fulvestrant
Letrozole
Palbociclib